According to the latest FactSet survey, 25 analysts have provided target price estimates for AbbVie (ABBV-US), with the median price revised upward from $265 to $273, representing an increase of approximately 3.02%. The highest estimate stands at $300, while the lowest is $218.

In terms of overall ratings, 32 analysts have evaluated AbbVie: 24 are positive and optimistic, 7 remain neutral, and 1 is conservative and pessimistic.

AbbVie closed today (10th) at $247.385. Over the past five days, the stock price has declined by 3.02%, while the S&P 500 index rose by 0.81%, indicating no significant short-term performance.

Source: FactSet. Data is for reference only and does not constitute investment advice.

FACT BOX

  • Source: PR Times
  • Category: Survey
  • Organizations: FactSet